Supplementary Figure 3 from TAK-960, a Novel, Orally Available, Selective Inhibitor of Polo-Like Kinase 1, Shows Broad-spectrum Preclinical Antitumor Activity in Multiple Dosing Regimens

MLA

Erik Kupperman, et al. Supplementary Figure 3 from TAK-960, a Novel, Orally Available, Selective Inhibitor of Polo-Like Kinase 1, Shows Broad-Spectrum Preclinical Antitumor Activity in Multiple Dosing Regimens. Apr. 2023. EBSCOhost, https://doi.org/10.1158/1535-7163.22498084.

APA

Erik Kupperman, Keisuke Kuida, Johnny Yang, Lilly Zhang, Zhe Nie, Sheldon Cao, Takashi Ichikawa, Takashi Sato, Tomohiro Kawamoto, Maki Hasegawa, Noriko Uchiyama, Saomi Murai, Isao Kaieda, Hitoshi Miyashita, Kouki Hikami, Kohei Honda, & Yuichi Hikichi. (2023). Supplementary Figure 3 from TAK-960, a Novel, Orally Available, Selective Inhibitor of Polo-Like Kinase 1, Shows Broad-spectrum Preclinical Antitumor Activity in Multiple Dosing Regimens. https://doi.org/10.1158/1535-7163.22498084

Chicago

Erik Kupperman, Keisuke Kuida, Johnny Yang, Lilly Zhang, Zhe Nie, Sheldon Cao, Takashi Ichikawa, et al. 2023. “Supplementary Figure 3 from TAK-960, a Novel, Orally Available, Selective Inhibitor of Polo-Like Kinase 1, Shows Broad-Spectrum Preclinical Antitumor Activity in Multiple Dosing Regimens,” April. doi:10.1158/1535-7163.22498084.